United States· US:80064-141_2b5b7036-1413-8c2f-e063-6394a90adf3b
Vyleesi
A bremelanotide product containing bremelanotide acetate, registered in United States by Palatin Technologies.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- BREMELANOTIDE ACETATE
- Manufacturer
- Palatin Technologies
- Country
- United States (US)
- ATC code
- G02CX05
- ATC class
- Bremelanotide
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- June 26, 2026
Packs & prices · 4
- ndc1180064-141-02
- ndc1180064141022 SYRINGE in 1 CARTON (80064-141-02) / .3 mL in 1 SYRINGE (80064-141-01)
- ndc1180064141044 SYRINGE in 1 CARTON (80064-141-04) / .3 mL in 1 SYRINGE (80064-141-01)
- ndc1180064-141-04
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
1 interaction on record for bremelanotide.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Bremelanotide · interactions on record
1 record
- 1 severe
Most severe, free to view
- NaltrexoneN07BB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under G02CX05
Bremelanotide, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5145f8ab-fb2e-40e1-a3bc-c7d2da079102 GET /v1/drugs/5145f8ab-fb2e-40e1-a3bc-c7d2da079102?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "1.75",
"substance": "BREMELANOTIDE ACETATE",
"productndc": "80064-141",
"dosage_form": "INJECTION",
"dea_schedule": null,
"strength_unit": "mg/.3mL",
"application_number": "NDA210557",
"marketing_category": "NDA"
}See everything about bremelanotide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.